LOS ANGELES, Dec. 12, 2022 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of what’s to come January 9, 2023 Deadline for filing a motion by lead plaintiff in the class action lawsuit filed on behalf of investors who have purchased or otherwise acquired Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) OWN securities between March 10, 2021 and October 4, 2022inclusive (the “Class Period”).

If you have suffered a loss on your Eiger investments or would like to inquire about potential claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/eiger-biopharmaceuticals-inc/. You can also contact GPM’s Charles H. Linehan at 310-201-9150, toll free at 888-773-9224, or email at shareholders@glancylaw.com to learn more about your rights.

In March 2022, Eiger announced that it would submit an Emergency Use Authorization (“EUA”) application to the U.S. Food and Drug Administration (FDA) for its mild-to-moderate COVID-19 drug, peginterferon lambda, based on the Results of the independent, multi-center TOGETHER study.

On September 6, 2022, Eiger provided an update on the status of its planned EUA request, announcing that “[f]After a cooperative and extensive exchange of information in front of the EEA with [the] FDA . . . the Agency has indicated that it is not yet able to assess whether the criteria for applying for and issuing an EUA are likely to be met.”

As a result of this news, the Eiger share price fell $2.51, or 29.4%, to close at $6.04 per share on September 6, 2022, hurting investors.

Then, on October 5, 2022, Eiger announced that it would no longer seek an EUA application after the FDA “denied the application for a pre-EUA meeting.” The company announced that the FDA “concluded that, based on the data [presented] unlikely to meet the legal criteria for issuing an EUA in the current context of the pandemic.”

On this…